0000904454-18-000183.txt : 20180216 0000904454-18-000183.hdr.sgml : 20180216 20180216164817 ACCESSION NUMBER: 0000904454-18-000183 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180214 FILED AS OF DATE: 20180216 DATE AS OF CHANGE: 20180216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Haskel William M. CENTRAL INDEX KEY: 0001524372 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36066 FILM NUMBER: 18621850 MAIL ADDRESS: STREET 1: ONE MEADOWLANDS PLAZA CITY: EAST RUTHERFORD STATE: NJ ZIP: 07073 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001178711 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330960223 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: (617) 807-6600 MAIL ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc DATE OF NAME CHANGE: 20090130 FORMER COMPANY: FORMER CONFORMED NAME: NOVACEA INC DATE OF NAME CHANGE: 20020724 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-02-14 0001178711 Paratek Pharmaceuticals, Inc. PRTK 0001524372 Haskel William M. C/O PARATEK PHARMACEUTICALS, INC. 75 PARK PLAZA, 4TH FLOOR BOSTON MA 02116 0 1 0 0 Sr. VP, Sec. & General Counsel Common Stock 2018-02-14 4 A 0 27000 0 A 62458 D Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on December 10, 2018, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. /s/ William M. Haskel 2018-02-16